Protein Nanomedicine Exerts Cytotoxicity toward CD34<sup>+</sup> CD38<sup>–</sup> CD123<sup>+</sup> Leukemic Stem Cells
- Publication date
- Publisher
Abstract
The efficacy of protein-vorinostat
nanomedicine (NV) is demonstrated
in leukemic stem cells (LSC) isolated from refractory acute myeloid leukemia (AML) patient samples, where
it successfully ablated both CD34<sup>+</sup> CD38<sup>–</sup> CD123<sup>+</sup> LSC and non-LSC “leukemic blast”
compartments, without inducing myelosuppression or hemotoxicity. Besides,
NV also exerted excellent synergistic lethality against leukemic bone
marrow cells (BMC) at lower concentrations (0.1 μM) in combination
with DNA methyltransferase (DNMT) inhibitor, decitabine. Considering
the extermination of resilient LSC and synergism with decitabine,
NV shows promise for clinical translation in the setting of a more
tolerable and effective epigenetic targeted therapy for leukemia